Adam Hubler

#RadOnc @UABradonc alum | @UTHSCMedicine alum | @tennalum

[Adam Hubler @AHub57]

@jryckman3 Not sure if I was the only one getting a 404 with the review link. I assumed it was AD’s review, so the link is below.

https://t.co/mcMaFdPhwz

[Bobby Koneru, MD @KoneruMd]

🚨The first American guidelines for low-dose radiotherapy in osteoarthritis were just published.

That’s not a small thing.

For decades, European centers have been treating OA with low-dose RT. American patients largely couldn’t access it. No formal guidance. No insurer framework. No roadmap for referring providers.

That changes today.

The American Radium Society Appropriate Use Criteria, published in the American Journal of Clinical Oncology, define exactly when and how to use LDRT for OA. Radiation oncologists, rheumatologists, physiatrists, and orthopedic surgeons built this together.

For insurers, this is the clinical framework they’ve been waiting for.

Honored to be a co-author alongside the global experts who made this possible.

[Adam Hubler @AHub57]

@jryckman3 Great thread Jeff! Curious, if such a convention were to be implemented in a hospital system, there is bound to be a learning curve for non-oncologic services to understand what they’re looking at. How do you envision helping these teams interpret these images?

[Adam Hubler @AHub57]

@DrSpratticus @piet_ost @jryckman3 @VedangMurthy Grasping at straws to postulate but maybe lymphopenia from increased marrow integral dose?

[Adam Hubler @AHub57]

@DrSpratticus @piet_ost @jryckman3 @VedangMurthy Having neither attended ESTRO nor seen pictures of the slides, I can’t speak to OS. Is there a biologically plausible mechanism that would cause adding pelvic RT to result in inferior OS?

PFS CIs suggest true difference is possible, but agree data to date most supports PO

[Elisabetta Bonzano MD, PhD @to_be_elizabeth]

📌 Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 10-year efficacy and late normal tissue effects from a multicentre, open-label, non-inferiority, phase 3, randomised controlled trial and 5-year efficacy results from a randomised axillary substudy
🔗 https://t.co/mk5GWyVkss
@OncoAlert #OncoAlertAF

[Shankar Siva @_ShankarSiva]

#ESTRO26 - 📣 FASTRACKII final results, median F/U of 5 years. Thank you patients, funders, investigators - #kidneycancer #kcsm
1) 100% Local Control: No local recurrences were observed at 36, 60, or 84 months.
2) 100% Cancer-Specific Survival
3) Grade 3 AEs remain at 10%

[Jeff Ryckman @jryckman3]

1/ 🚨 New @NEJM: Perioperative enfortumab vedotin + pembrolizumab (EV+pembro) in MIBC (KEYNOTE-905)

Congrats to the authors on an important randomized phase 3 trial in a tough, cisplatin-ineligible population 👏

Let’s walk through it 👇

[Adam Hubler @AHub57]

So proud to see our PD get recognized for some of the incredible work he has done in his (still early) career. Brilliant physician and altogether wonderful person

[UAB Radiation Oncology @UABradonc]

Congratulations to Samuel Marcrom, M.D., on his President’s Corner feature with @ASTRO_org. His work at @uabheersink Dept. of Radiation Oncology is shaping the future of radiation oncology!

Watch here: https://t.co/BT2kSl2OZW

[Adam Hubler @AHub57]

@toddscarbrough @DoctorJSpicer @myESMO @BrendonStilesMD @DrewMoghanaki @FordePatrick @biniamkidaneMD @finn_corinne @sara_najmeh @JonathanCools @LFerri123 @StephenVLiu Poorly worded on my part . Intended to mean stage III shouldn’t be RT alone, and stage I-II undergoing SBRT should have better EFS if BED >100

[Corey Speers @cwspeers]

Honored to host visiting professor Dr. Neil Desai from UT Southwestern at @UABRadOnc—an absolute masterclass on the now and next of prostate cancer care: smarter imaging, refined dosing, and shared decision-making. Thank you for raising the bar! #ProstateCancer #RadOnc @ndesai2005

[Jason Beckta @drbeckta]

"We might have blown off a bit of artery with radiation - we do that sometimes, we're silly gooses - and since you might have a wee bit of exploded artery, I'm going to do an EKG, which is the gold standard next step in the management of exploded artery."

[Neha Vapiwala @NehaVapiwala]

👏 dear authors, for reminding @ASTRO_org & each of us of our responsibility to demystify RT & tackle dangerous misinformation, hiding in plain sight. RadOnc excels in scientific exploration - it’s past time for a better approach to disseminating it. Data to dialogue #astro2026

[Corey Speers @cwspeers]

🚨Happening NOW at UAB: Kicking off an outstanding adaptive radiation therapy seminar before heading to #ASCO25! First up—Dr. Lauren Henke breaking down the future of individualized treatment in real-time. Incredible science, inspiring discussion. Let’s go! 💥📡@ONealCancerUAB

[Daniel E Spratt @DrSpratticus]

X-torial: Cleaning up the misinformation about @JoeBiden and #ProstateCancer that I am reading everywhere.

The purpose of this is to provide education from someone who treats and studies PCa for a living, lead the USA @NCCN PCa guidelines, hold leadership in @NRGonc @theNCI @US_FDA and dedicated my career to help men and their families suffering from PCa

@nytimes @WSJ @FoxNews @CNN @NBCNews @Reuters @ASCO @PCFnews @DeptofDefense

[Adam Hubler @AHub57]

@UABradonc @UABHeersink We’re so excited to welcome these three incredible future #RadOnc superstars!

[Penn State Wrestling @PennStateWREST]

Tyler Kasak 💪

#PSUwr

[Adam Hubler @AHub57]

Would any consider cis/etop/placebo an appropriate control arm for ES-SCLC?

Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer https://t.co/oOq7IK9tLo